Wellcome Trust

Cultivarium develops open-source tools for life scientists to expand access to novel microorganisms and research.

RenBio specializes in developing antibody-based therapies for cancer and inflammatory diseases. Its proprietary MYO technology enables the creation of antibodies tailored to treat rare diseases, viral infections, autoimmune disorders, and other conditions.

Vaxxas is a biotechnology company developing needle-free vaccination technology. It uses proprietary dry-coating technology to eliminate or significantly reduce the need for vaccine refrigeration, easing storage and transportation logistics.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

data.org seeks to democratize and reimagine the use of data science to tackle society’s greatest challenges and improve lives across the globe. Our current initiatives aim to advance inclusive growth, build capacity, mitigate and adapt to climate change and fight pandemics.

Generate Capital builds, owns, operates, and finances infrastructure assets across energy storage, solar power, energy efficiency, biomass, agriculture, wastewater treatment, mobility, and water resources. It offers standard financial products and custom-tailored solutions to technology manufacturers, project developers, contractors, and integrators.

Oxitec Limited is a biotechnology company that develops genetic solutions for controlling insects that transmit diseases and damage crops. It uses the Sterile Insect Technique (SIT) enhanced with genetics and molecular biology to create self-limiting insect strains, aiming to reduce populations of pests such as mosquitoes and moths in an environmentally friendly manner.

Founded in 1998, TAE Technologies is dedicated to developing clean fusion energy through advanced particle accelerator and plasma physics. Its mission is to create a sustainable energy source with no harmful byproducts.

ThinkSono Ltd is a London-based company that specializes in the development of software for diagnosing deep vein thrombosis (DVT) at the point of care. Founded in 2016, the firm has created an innovative automatic diagnostic system that leverages deep learning technologies to guide healthcare professionals in using a portable scanner. This system instructs users on where to place the probe on the skin to capture ultrasound images, facilitating rapid diagnosis. By enabling healthcare providers to assess DVT within ten minutes, ThinkSono aims to improve patient outcomes and streamline the diagnostic process in various medical settings.

Transformative AI Limited, incorporated in 2016 and based in London, United Kingdom, develops innovative healthcare solutions aimed at predicting life-threatening medical events, specifically the onset of sudden cardiac arrest. The company's patent-pending algorithm processes and translates clinical data into real-time predictive assessments, offering advance warning to patients and healthcare providers. This proactive approach empowers users to prepare for intervention, ultimately enhancing patient outcomes and promoting longer, healthier lives. Through its advanced technology, Transformative AI seeks to revolutionize the way healthcare systems manage critical cardiac incidents, prioritizing prevention and timely response.

Verne Global is a data center provider delivering sustainable, high-performance computing infrastructure. It offers colocation and HPC-as-a-Service, including DGX-Ready Hosting, for AI, earth sciences, engineering, financial services, life sciences, and scientific research. The company operates multiple data centers across Iceland, Finland, and a central London hub, with all Nordic facilities powered by 100% renewable energy. Its Iceland campus is located in Keflavík on a site chosen for low natural-disaster risk, enabling low-cost, carbon-neutral power and reduced emissions. Verne Global focuses on enabling scalable digital infrastructure with low latency and strong connectivity, supporting customers to deploy AI and other intensive workloads in an environmentally friendly and cost-efficient manner.

Mologic Ltd. is a UK-based company established in 2003 that specializes in the development of diagnostic products for the research market. The company focuses on various areas including clinical research, diagnostic development, enzyme-free blood glucose monitoring, microbial physiology, peritoneal dialysis, and wound care research. Mologic offers a range of diagnostic tools such as lateral flow kits for measuring human Alpha-1 antitrypsin, desmosine ELISA kits for urinary assays, and fMLP assay kits designed for solid-phase competition assays. In addition to its product offerings, Mologic provides services in assay and reagent development, clinical evaluation studies, and the creation of high-performance antibodies for challenging targets. The company's mission is to enhance patient care and quality of life, contributing to significant advancements in healthcare and education.

Prokarium is a biopharmaceutical company developing microbial immunotherapy and cancer vaccines through a synthetic biology platform. It focuses on immuno-oncology programs designed to evoke durable antitumor responses by re-engineering biological processes to stimulate the immune system. The lead program targets bladder cancer, aiming to transform treatment by orchestrating immune-driven, long-lasting antitumor effects.

Kineta is a clinical-stage biotechnology company based in Seattle, Washington. Founded in 2007, it focuses on developing immunology-based therapies for oncology and virology. Notable products include KCP-506 for chronic pain treatment and LHF-535 for antiviral therapy against viruses like Lassa. Kineta also has drug development programs targeting RIG-I and VISTA for cancer immunotherapy.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

Karuna Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for psychiatric and neurological disorders. Its primary focus is on creating novel therapies to address disabling neuropsychiatric conditions, with a particular emphasis on schizophrenia and the behavioral symptoms of Alzheimer's disease.

Karuna Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for psychiatric and neurological disorders. Its primary focus is on creating novel therapies to address disabling neuropsychiatric conditions, with a particular emphasis on schizophrenia and the behavioral symptoms of Alzheimer's disease.

Karuna Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for psychiatric and neurological disorders. Its primary focus is on creating novel therapies to address disabling neuropsychiatric conditions, with a particular emphasis on schizophrenia and the behavioral symptoms of Alzheimer's disease.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.

DoorDash is an on-demand delivery platform that connects merchants, consumers, and delivery personnel through a marketplace app. The company enables merchants to reach customers, manage delivery, analytics, merchandising, payment processing, and customer support, and also offers a white-label logistics service called DoorDash Drive. Founded in 2013 and headquartered in San Francisco, DoorDash operates in the United States and internationally, and expanded into Europe and Asia through the acquisition of Wolt in 2022. While initially focused on restaurant delivery, the platform also serves grocery, retail, and pet-supply segments, creating a last-mile delivery infrastructure and ongoing experimentation with innovative delivery methods, including drone concepts. The service aims to help local businesses grow by facilitating online ordering, marketing, and delivery execution, connecting customers with both local and national brands.

CorInnova Incorporated, founded in 2004 and based in Houston, Texas, specializes in device-based therapies aimed at treating congestive heart failure. The company is known for its innovative non-blood-contacting soft robotic cardiac assist device, which has the potential to significantly increase the number of heart failure patients eligible for life-saving device therapies. By focusing on advanced technological solutions, CorInnova seeks to improve outcomes for individuals suffering from this serious condition.

Instacart operates a grocery delivery platform in the United States and Canada, partnering with local and national grocers to offer a broad catalog of items for home delivery. Customers can mix items from multiple stores in a single order, and orders are picked and delivered by shoppers who are typically independent contractors. The platform supports fast delivery, including options in as little as an hour. Instacart earns revenue from service fees based on order value and by selling advertising to consumer-packaged goods brands. The service catalogs about 500,000 items and attracts about 8 million monthly active users, supported by roughly 600,000 shoppers.

Founded in 2008, ResearchGate operates an online professional networking platform for scientists worldwide. It facilitates the sharing of research findings, collaboration among peers, job searches within academia, and access to statistical data on citations.

Exonate is a biotechnology company focused on developing small molecule drugs that modulate alternative messenger RNA splicing. It specializes in ophthalmology, with a primary focus on treating diabetic retinopathy and diabetic macular oedema (DMO), as well as wet age-related macular degeneration (wAMD). The company's lead program aims to provide superior efficacy through topical agents in preclinical models of wAMD.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the discovery and development of fully human monoclonal antibody therapeutics. Founded in 2009, Kymab utilizes its proprietary Kymouse and IntelliSelect platforms to develop therapies targeting challenging and novel drug targets within immuno-oncology and immune-mediated diseases. The company's comprehensive antibody platforms are designed to maximize the diversity of human antibodies, enabling the creation of novel therapeutic options for conditions such as cancer and autoimmune diseases. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to advance its research and development efforts. As a subsidiary of Kymab Group Limited, the company is focused on addressing unmet medical needs through innovative antibody-based therapies.

Founded in 2011, Acesion Pharma is a Danish biotech company dedicated to developing safe and tolerable treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. The company focuses on inhibiting specific ion channels in heart cells to regulate the heart's rhythm and prevent AF recurrence.

Phononic designs and manufactures solid-state cooling and heating solutions. Its products include thermoelectric devices and heat pumps used in electronics cooling, refrigeration, and climate control applications. Founded in 2008, the company is headquartered in Durham, North Carolina.

Pearl is dedicated to bringing the latest advanced driver assistance features to all drivers on the road today. Products created by the team at Pearl leverage the very same technologies that are the building blocks of the autonomous vehicle. By deploying these features in the aftermarket, Pearl enables more consumers to have access to these key technologies.

DoorDash is an on-demand delivery platform that connects merchants, consumers, and delivery personnel through a marketplace app. The company enables merchants to reach customers, manage delivery, analytics, merchandising, payment processing, and customer support, and also offers a white-label logistics service called DoorDash Drive. Founded in 2013 and headquartered in San Francisco, DoorDash operates in the United States and internationally, and expanded into Europe and Asia through the acquisition of Wolt in 2022. While initially focused on restaurant delivery, the platform also serves grocery, retail, and pet-supply segments, creating a last-mile delivery infrastructure and ongoing experimentation with innovative delivery methods, including drone concepts. The service aims to help local businesses grow by facilitating online ordering, marketing, and delivery execution, connecting customers with both local and national brands.

Quethera Limited is a biotechnology company based in Canterbury, United Kingdom, focused on developing gene therapy treatments for glaucoma and other ophthalmic diseases. Established in 2013, the company aims to address progressive visual loss associated with these conditions, particularly in patients experiencing accelerated deterioration of their visual fields. Quethera collaborates with leading experts in the field of glaucoma to design and conduct clinical trials that assess the efficacy and safety of its innovative therapies. With a strong foundation in gene therapeutic design and development, Quethera is advancing its pipeline from preclinical testing into clinical development, striving to provide effective treatment solutions for common blinding eye diseases. As of 2018, Quethera operates as a subsidiary of Astellas Pharma Inc.

Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, specializing in the development of innovative mucosal vaccines for infectious diseases. The company's lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infections. Mucosis utilizes its proprietary Mimopath technology, which allows for needle-free administration via the nose or mouth, effectively engaging the innate immune system through Toll-like receptor 2 (TLR2) to stimulate a robust adaptive immune response. This approach has shown promise in both animal and human proof-of-concept studies, demonstrating broad protection against various pathogens, including RSV, pneumococci, and influenza.

MediSieve Ltd. is a London-based medical device company specializing in Magnetic Blood Filtration (MBF) technology aimed at treating blood-borne diseases. Founded in 2014, the company has developed a system that utilizes a magnetic filter to physically remove infected blood cells from a patient's bloodstream. The process involves circulating blood through an external loop where targeted magnetic particles are infused, binding to disease-relevant targets. This filtered blood then passes through a magnetic filter that captures the particles and bound targets, allowing the unaffected blood to return to the patient without the particles entering their body. MediSieve's innovative approach is applicable to various conditions, including malaria, leukaemia, sepsis, and other blood-borne diseases, enhancing the efficacy and safety of existing therapies. The company operates out of the Imperial Incubator in White City, London, where it conducts product development and validation in its dedicated laboratory facilities.

Elastagen is a clinical-stage medical company focused on developing products based on human protein tropoelastin, a vital component for tissues that require elasticity, such as skin and blood vessels. The company has created a synthetic version of elastin that mirrors the natural protein found in the human body, allowing for innovative applications in skin rejuvenation, scar remodeling, and tissue repair. Elastagen's offerings include injectable synthetic human elastin and chemically cross-linked tropoelastin for aesthetic purposes, aimed at helping patients maintain skin elasticity and suppleness. Founded through the acquisition of intellectual property from research conducted by Prof Weiss at the University of Sydney, Elastagen has attracted significant investment from both Australian and international life science venture capital groups. Its operations have grown from Australia to include production facilities in Europe and clinical activities in the UK.

Klarna is a technology-driven payments company that provides a platform for connecting consumers and merchants with flexible payment options for online and offline shopping. It offers direct payments, pay-after-delivery options, and installment plans, supported by a mobile app that enhances the shopping experience with flexible payment options and cashback rewards. The company operates across multiple countries and serves merchants with payment solutions and tailored advertising services, including messaging and insights features. Klarna is known for its buy now, pay later model, enabling interest-free financing for purchases divided into installments.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.

DoorDash is an on-demand delivery platform that connects merchants, consumers, and delivery personnel through a marketplace app. The company enables merchants to reach customers, manage delivery, analytics, merchandising, payment processing, and customer support, and also offers a white-label logistics service called DoorDash Drive. Founded in 2013 and headquartered in San Francisco, DoorDash operates in the United States and internationally, and expanded into Europe and Asia through the acquisition of Wolt in 2022. While initially focused on restaurant delivery, the platform also serves grocery, retail, and pet-supply segments, creating a last-mile delivery infrastructure and ongoing experimentation with innovative delivery methods, including drone concepts. The service aims to help local businesses grow by facilitating online ordering, marketing, and delivery execution, connecting customers with both local and national brands.

Verne Global is a data center provider delivering sustainable, high-performance computing infrastructure. It offers colocation and HPC-as-a-Service, including DGX-Ready Hosting, for AI, earth sciences, engineering, financial services, life sciences, and scientific research. The company operates multiple data centers across Iceland, Finland, and a central London hub, with all Nordic facilities powered by 100% renewable energy. Its Iceland campus is located in Keflavík on a site chosen for low natural-disaster risk, enabling low-cost, carbon-neutral power and reduced emissions. Verne Global focuses on enabling scalable digital infrastructure with low latency and strong connectivity, supporting customers to deploy AI and other intensive workloads in an environmentally friendly and cost-efficient manner.

Phononic designs and manufactures solid-state cooling and heating solutions. Its products include thermoelectric devices and heat pumps used in electronics cooling, refrigeration, and climate control applications. Founded in 2008, the company is headquartered in Durham, North Carolina.

Omniox is a biopharmaceutical company focused on developing innovative treatments for diseases associated with hypoxia, a condition characterized by inadequate oxygen levels in tissues. This lack of oxygen is linked to various serious health issues, including certain cancers and cardiovascular diseases. The company utilizes its proprietary H-NOX platform technology, which is designed to deliver oxygen and nitric oxide specifically to hypoxic tissues. This targeted approach aims to restore normal tissue function and improve patient outcomes by addressing the underlying causes of hypoxia-related diseases. Through its advancements in biologics, Omniox seeks to provide meaningful therapeutic benefits and enable healthcare professionals to develop effective oxygen-based therapies that enhance patient health and recovery.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

AirStrip Technologies, Inc. is a provider of technology solutions designed to enhance collaboration among caregivers and improve patient care. Its flagship product, AirStrip ONE, is a data- and vendor-agnostic platform that enables clinicians to access critical patient information, including real-time waveform data, from various hospital monitoring systems on their mobile devices. This platform facilitates communication and data sharing across the healthcare continuum, helping to break down barriers related to geography, technology, and workflows. Additionally, AirStrip offers Accelerator Services, which provide essential business intelligence to support clinical interoperability. The company's solutions address a range of healthcare challenges, including digital ECG snippets, alarm management, remote patient monitoring, and maternal/fetal data management. Founded in 2004 and headquartered in San Antonio, Texas, AirStrip serves a diverse clientele that includes health systems, healthcare providers, and information technology clients within the healthcare sector.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the discovery and development of fully human monoclonal antibody therapeutics. Founded in 2009, Kymab utilizes its proprietary Kymouse and IntelliSelect platforms to develop therapies targeting challenging and novel drug targets within immuno-oncology and immune-mediated diseases. The company's comprehensive antibody platforms are designed to maximize the diversity of human antibodies, enabling the creation of novel therapeutic options for conditions such as cancer and autoimmune diseases. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to advance its research and development efforts. As a subsidiary of Kymab Group Limited, the company is focused on addressing unmet medical needs through innovative antibody-based therapies.

Integrated Diagnostics Inc. is a company focused on developing laboratory-based blood diagnostic tools that facilitate the early diagnosis of complex diseases through non-invasive blood tests. Established in 2005 and headquartered in Seattle, Washington, the company specializes in products that monitor multiple molecular markers simultaneously, offering valuable insights for conditions such as lung cancer. One of its key offerings is Xpresys Lung, a molecular blood test designed to provide objective information for assessing pulmonary nodules. Integrated Diagnostics is committed to leveraging advanced technologies to create a pipeline of innovative diagnostic products aimed at enhancing disease management for conditions including cancer, diabetes, and Alzheimer's. The company operates under a strategic partnership with Agilent Technologies Inc. and has been functioning as a subsidiary of Biodesix, Inc. since 2018.

Founded in 2011, Acesion Pharma is a Danish biotech company dedicated to developing safe and tolerable treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. The company focuses on inhibiting specific ion channels in heart cells to regulate the heart's rhythm and prevent AF recurrence.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

VenatoRx Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing novel anti-infective agents. Established in 2010, the company focuses on addressing multi-drug resistant bacterial infections, including those caused by MRSA, Pseudomonas spp., and Salmonella spp.

Treventis Corporation is focused on the treatment and prevention of protein misfolding diseases using its proprietary, patent-pending discovery engine known as Common Conformational Morphology (CCM). This innovative platform allows the company to identify druggable active sites in misfolded protein targets through a combination of unique in silico models and extensive expertise in drug model development across various testing methodologies. Treventis's lead program concentrates on developing anti-misfolding small molecules particularly aimed at tauopathy, which is closely linked to Alzheimer’s disease. Additionally, the company is exploring applications of its technology in oncology and other neurodegenerative disorders, showcasing the versatility and potential of its approach to rational drug design. The company's objectives include discovering compounds that can effectively block amyloid toxicity and improve treatment options for Alzheimer's patients, ideally with minimized side effects.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

Trino Therapeutics is a drug discovery and early development company specializing in anti-inflammatory therapeutics. The company is focused on creating drug candidates from a novel class of compounds known as indane dimers, which are derived from a Taiwanese fern. Its lead candidate aims to be a first-in-class treatment for inflammatory bowel disease (IBD), specifically targeting conditions like ulcerative colitis and Crohn’s disease. In addition to IBD, Trino's proprietary drug class shows potential for broad anti-inflammatory applications, including dermatological, pulmonary, and autoimmune diseases. Through its innovative approach, Trino Therapeutics addresses significant unmet medical needs in the field of inflammatory conditions.

Canbex Therapeutics, Ltd. is a London-based company focused on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative diseases. Founded in 2005, the company addresses the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex Therapeutics strives to enhance the quality of life for individuals suffering from this serious and often incurable condition, with the objective of establishing a new standard in the treatment of spasticity.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Haemostatix Ltd. is a biotechnology company based in Nottingham, United Kingdom, founded in 2003 as a spin-out from the University of Leicester. The company specializes in developing a peptide-based platform technology aimed at creating innovative products for controlling surgical bleeding and promoting tissue repair. Its primary product, PeproStat, is a coagulant that can be directly applied to surgical wounds to effectively manage bleeding. Haemostatix’s technology utilizes a specific peptide sequence that binds to fibrinogen, a crucial protein in clot formation. This platform supports a diverse pipeline of first-in-class hemostatic products designed to address various bleeding scenarios, including those encountered in surgery, trauma, and among leukaemic patients. Haemostatix operates as a subsidiary of Ergomed plc.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.

AirStrip Technologies, Inc. is a provider of technology solutions designed to enhance collaboration among caregivers and improve patient care. Its flagship product, AirStrip ONE, is a data- and vendor-agnostic platform that enables clinicians to access critical patient information, including real-time waveform data, from various hospital monitoring systems on their mobile devices. This platform facilitates communication and data sharing across the healthcare continuum, helping to break down barriers related to geography, technology, and workflows. Additionally, AirStrip offers Accelerator Services, which provide essential business intelligence to support clinical interoperability. The company's solutions address a range of healthcare challenges, including digital ECG snippets, alarm management, remote patient monitoring, and maternal/fetal data management. Founded in 2004 and headquartered in San Antonio, Texas, AirStrip serves a diverse clientele that includes health systems, healthcare providers, and information technology clients within the healthcare sector.

Siluria Technologies is a materials innovation company focused on addressing global challenges in the natural gas, chemicals, and fuel industries. By leveraging advancements in nanotechnology, biotechnology, and chemical engineering, Siluria has created a platform that enables the efficient production of chemicals and fuels from natural gas, a more abundant and cost-effective resource compared to oil. Their technology allows for the conversion of natural gas into higher-value products, including liquid fuels such as gasoline, diesel, and jet fuel, through the integration of nanomaterials and catalyst development. Siluria's research and engineering teams are actively working to commercialize their solutions and engage with major chemical and fuel companies to bring their technology to pilot-scale production.

Kuur Therapeutics Limited is a biopharmaceutical company focused on developing, manufacturing, and commercializing CAR-NKT cell immunotherapies for cancer treatment. The company is advancing a pipeline of immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics specializes in engineered off-the-shelf CAR-NKT cell therapies that leverage the natural biology of a specific subset of cytotoxic T cells known as natural killer T cells. This innovative approach aims to provide effective treatment options for a wide range of solid and hematological tumors. The company conducts clinical trials to demonstrate the efficacy of its CAR-NKT cell products, thereby striving to transform cancer care. Founded in 2005 and based in London, Kuur Therapeutics was previously known as Cell Medica Limited before its rebranding in February 2020.

Castlight Health is dedicated to simplifying the healthcare experience and promoting healthier, more productive lives. Its health navigation platform integrates with various health vendors, benefits resources, and plan designs, creating a comprehensive application that addresses diverse health needs. By tailoring guidance to individual profiles, Castlight assists users, whether they are healthy, managing chronic conditions, or seeking medical care, in accessing optimal resources. The company aims to help organizations manage rising healthcare costs and enhance the value of their benefits investments. Since its inception, Castlight has introduced innovative solutions such as data-driven price transparency tools and a consumer-friendly wellbeing platform. Currently, it serves millions of users and partners with numerous large employers, positioning itself as a key player in the healthcare sector. Castlight is headquartered in San Francisco.

Sapphire Energy, Inc. is a pioneering company based in San Diego, California, that focuses on producing renewable solutions from algae. Founded in 2007, the company utilizes sunlight, carbon dioxide, non-potable water, and non-arable land to cultivate algae in outdoor ponds, which generates biomass that can be transformed into high-value products, including oils, aquaculture and animal feeds, and renewable fuels. Sapphire Energy is unique in its approach, as its processes rely solely on photosynthetic microorganisms, distinguishing them from traditional biofuels that often depend on food crops. The company's products are designed to enhance and replace petroleum-based materials while being compatible with existing infrastructure. Sapphire operates a research and development facility in Las Cruces, New Mexico, and is developing an Integrated Algal BioRefinery in Columbus, New Mexico, with the aim of advancing the renewable energy landscape and contributing to a more sustainable planet.

Integrated Diagnostics Inc. is a company focused on developing laboratory-based blood diagnostic tools that facilitate the early diagnosis of complex diseases through non-invasive blood tests. Established in 2005 and headquartered in Seattle, Washington, the company specializes in products that monitor multiple molecular markers simultaneously, offering valuable insights for conditions such as lung cancer. One of its key offerings is Xpresys Lung, a molecular blood test designed to provide objective information for assessing pulmonary nodules. Integrated Diagnostics is committed to leveraging advanced technologies to create a pipeline of innovative diagnostic products aimed at enhancing disease management for conditions including cancer, diabetes, and Alzheimer's. The company operates under a strategic partnership with Agilent Technologies Inc. and has been functioning as a subsidiary of Biodesix, Inc. since 2018.

PTC Therapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing treatments for rare genetic disorders. Its portfolio includes approved drugs like Translarna (ataluren) and Emflaza (deflazacort), as well as pipeline candidates targeting various rare diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and certain cancers.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Sapiens is a leading provider of software solutions tailored to the insurance industry, serving various sectors including general insurance, life and pensions, reinsurance, and retirement markets. They offer comprehensive end-to-end solutions and business decision management software.

Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, Sapiens operates from offices in Eindhoven, the Netherlands, and Munich, Germany. The company is dedicated to developing a high-resolution, MRI-compatible DBS system designed to enhance patient comfort and improve therapeutic outcomes, particularly for individuals with Parkinson's disease. Sapiens’ innovative approach includes a unique steering brain stimulation system and image-guided programming, both of which are based on patented technologies.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Siluria Technologies is a materials innovation company focused on addressing global challenges in the natural gas, chemicals, and fuel industries. By leveraging advancements in nanotechnology, biotechnology, and chemical engineering, Siluria has created a platform that enables the efficient production of chemicals and fuels from natural gas, a more abundant and cost-effective resource compared to oil. Their technology allows for the conversion of natural gas into higher-value products, including liquid fuels such as gasoline, diesel, and jet fuel, through the integration of nanomaterials and catalyst development. Siluria's research and engineering teams are actively working to commercialize their solutions and engage with major chemical and fuel companies to bring their technology to pilot-scale production.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Canbex Therapeutics, Ltd. is a London-based company focused on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative diseases. Founded in 2005, the company addresses the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex Therapeutics strives to enhance the quality of life for individuals suffering from this serious and often incurable condition, with the objective of establishing a new standard in the treatment of spasticity.

Beyond Oblivion is a music and technology company founded in 2008 by its CEO, Adam Kidron. Its principle shareholders are Wellcome Trust, News Corporation, Allen & Company, Intertrust Technologies Corporation, and Adam Kidron. Beyond Oblivion's first go-to-market product is boinc. boinc is a magnetic and social music service that distributes a vast legal music library from a cloud (supplied by majors, independents, and artists the world over), and embeds the right to download and PLAY IT ALL within devices like PCs, tablets, autos and smartphones. boinc replaces paid-download, paid subscription, and advertiser-supported services with an inexpensive one-time, lifetime-of-device usage fee - paying copyright owners a micro-royalty per play, no matter if the original file were legally or illegally downloaded.

Wonga is a UK-based online lender specializing in small, short-term cash advances. It uses advanced risk assessment technology to make swift, responsible lending decisions. Customers can customize loan amounts (up to £750) and durations (5 to 30 days) before applying, with funds deposited within minutes. Wonga's fully automated system offers more speed and flexibility than traditional credit options, aiming to help consumers manage temporary cash shortfalls rather than long-term debt. It has been recognized for its innovative technology, winning awards such as the Red Herring Europe 100 and the National Business Awards.

Haemostatix Ltd. is a biotechnology company based in Nottingham, United Kingdom, founded in 2003 as a spin-out from the University of Leicester. The company specializes in developing a peptide-based platform technology aimed at creating innovative products for controlling surgical bleeding and promoting tissue repair. Its primary product, PeproStat, is a coagulant that can be directly applied to surgical wounds to effectively manage bleeding. Haemostatix’s technology utilizes a specific peptide sequence that binds to fibrinogen, a crucial protein in clot formation. This platform supports a diverse pipeline of first-in-class hemostatic products designed to address various bleeding scenarios, including those encountered in surgery, trauma, and among leukaemic patients. Haemostatix operates as a subsidiary of Ergomed plc.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the discovery and development of fully human monoclonal antibody therapeutics. Founded in 2009, Kymab utilizes its proprietary Kymouse and IntelliSelect platforms to develop therapies targeting challenging and novel drug targets within immuno-oncology and immune-mediated diseases. The company's comprehensive antibody platforms are designed to maximize the diversity of human antibodies, enabling the creation of novel therapeutic options for conditions such as cancer and autoimmune diseases. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to advance its research and development efforts. As a subsidiary of Kymab Group Limited, the company is focused on addressing unmet medical needs through innovative antibody-based therapies.

Castlight Health is dedicated to simplifying the healthcare experience and promoting healthier, more productive lives. Its health navigation platform integrates with various health vendors, benefits resources, and plan designs, creating a comprehensive application that addresses diverse health needs. By tailoring guidance to individual profiles, Castlight assists users, whether they are healthy, managing chronic conditions, or seeking medical care, in accessing optimal resources. The company aims to help organizations manage rising healthcare costs and enhance the value of their benefits investments. Since its inception, Castlight has introduced innovative solutions such as data-driven price transparency tools and a consumer-friendly wellbeing platform. Currently, it serves millions of users and partners with numerous large employers, positioning itself as a key player in the healthcare sector. Castlight is headquartered in San Francisco.

Biota Holdings Limited is an Australian biotechnology company focused on the discovery, development, and commercialization of anti-infective drugs, primarily targeting respiratory diseases such as influenza. The company is known for creating zanamivir, an in-class neuraminidase inhibitor marketed as Relenza for the treatment of seasonal influenza. Biota has also explored treatments for hepatitis C virus infections through nucleoside analogues licensed to Boehringer Ingelheim and is developing candidates for respiratory syncytial virus disease. Currently, Biota is conducting clinical trials for its lead compound targeting human rhinovirus infections in patients with compromised respiratory or immune systems. The company has established a partnership with Daiichi Sankyo to advance the development of second-generation antiviral drugs for influenza and has expanded its portfolio by acquiring antibacterial assets from MaxThera Inc.

Achaogen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in the development and commercialization of antibacterial agents targeting multi-drug resistant (MDR) gram-negative infections. The company's primary focus is on plazomicin, which is intended for treating serious bacterial infections caused by MDR enterobacteriaceae, including carbapenem-resistant strains. Additionally, Achaogen is developing C-Scape, an orally-administered combination of clavulanate and ceftibuten aimed at addressing serious infections linked to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established collaborations with various organizations, including Thermo Fisher Scientific and Ionis Pharmaceuticals, to support its drug development efforts. The company was incorporated in 2002, but faced financial difficulties, leading to a Chapter 11 bankruptcy filing in 2019, which culminated in a liquidation plan approved in 2020. All of Achaogen's revenue has been derived from government contracts for research and development within the United States.

Mintaka Foundation is finding simple health solutions for developing countries using advanced technology.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.

Oxagen Limited is a biopharmaceutical company based in London, United Kingdom, focused on developing and commercializing anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company specializes in small molecule drugs that target the CRTH2 receptor, which plays a key role in initiating and maintaining allergic responses. Oxagen's pipeline includes OC000459, an oral CRTH2 antagonist designed for eosinophilic asthma and allergic rhinoconjunctivitis. Additionally, the company addresses various inflammatory diseases such as autoimmune disease, inflammatory bowel disease, psoriasis, allergy, and rheumatoid arthritis. Founded in 1996, Oxagen serves customers globally, including in the United Kingdom, Russia, CIS countries, and other international markets.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.

Integrated Diagnostics Inc. is a company focused on developing laboratory-based blood diagnostic tools that facilitate the early diagnosis of complex diseases through non-invasive blood tests. Established in 2005 and headquartered in Seattle, Washington, the company specializes in products that monitor multiple molecular markers simultaneously, offering valuable insights for conditions such as lung cancer. One of its key offerings is Xpresys Lung, a molecular blood test designed to provide objective information for assessing pulmonary nodules. Integrated Diagnostics is committed to leveraging advanced technologies to create a pipeline of innovative diagnostic products aimed at enhancing disease management for conditions including cancer, diabetes, and Alzheimer's. The company operates under a strategic partnership with Agilent Technologies Inc. and has been functioning as a subsidiary of Biodesix, Inc. since 2018.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

Chroma Therapeutics Ltd., established in 2000, is a privately-held biotechnology company based in Abingdon, UK. It specializes in developing novel small molecule drugs for targeted cancer and inflammation treatments, drawing from chromatin biology and innovative cell accumulation approaches. The company's pipeline includes Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor for cancer treatment; and CHR-2845, a targeted solution for hematological malignancies. Chroma has built a strong network of academic collaborators and holds the first systematic assembly of intellectual property in chromatin biology, aiming to create substantial shareholder value through its innovative product pipeline targeting high-prevalence diseases.

VaxInnate is a vaccine company founded in 2002 and headquartered in Cranbury, New Jersey, that specializes in developing vaccines for various infectious diseases, including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. The company utilizes a unique technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, enhancing the immunogenicity and efficacy of its vaccines. This innovative approach allows for quicker treatment initiation, increasing the likelihood of successful patient outcomes. VaxInnate operates within the healthcare, health diagnostics, and biotechnology sectors, focusing on advancing vaccine development to address significant global health challenges.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Phico Therapeutics is a biotechnology company focused on developing innovative antibiotics to combat antibacterial resistance. Its proprietary platform, SASPject, delivers anti-bacterial proteins to specific bacterial species using targeted non-delivery vehicles. The company's pipeline includes treatments for Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, and Staphylococcus aureus.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

Qwell's goal is to develop a new family of small-molecule drugs, derived from a plant source, that have a potent ability to fight tumors and excess inflammation of skin cells.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Sapphire Energy, Inc. is a pioneering company based in San Diego, California, that focuses on producing renewable solutions from algae. Founded in 2007, the company utilizes sunlight, carbon dioxide, non-potable water, and non-arable land to cultivate algae in outdoor ponds, which generates biomass that can be transformed into high-value products, including oils, aquaculture and animal feeds, and renewable fuels. Sapphire Energy is unique in its approach, as its processes rely solely on photosynthetic microorganisms, distinguishing them from traditional biofuels that often depend on food crops. The company's products are designed to enhance and replace petroleum-based materials while being compatible with existing infrastructure. Sapphire operates a research and development facility in Las Cruces, New Mexico, and is developing an Integrated Algal BioRefinery in Columbus, New Mexico, with the aim of advancing the renewable energy landscape and contributing to a more sustainable planet.

Endotis discovers, develops, and manufactures cardiovascular therapeutics. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology areas. Its portfolio of products includes EP217609, a neutralizable anti-coagulant for managing extracorporeal blood circulation during open-heart surgery; FondaParinux, an injectable drug for the prevention and treatment of venous thromboembolism; and an oral anti-coagulant for stroke prevention in atrial fibrillation. Endotis was founded in 2003 and is based in Romainville, France.

Senexis is operates as a small-molecule drug discovery company, engages in discovering compounds for the treatment of ageing-related diseases resulting from the toxicity of amyloid-like proteins. The company offers small molecule inhibitors of amyloid aggregation and toxicity as therapeutic agents to inhibit the pathogenic process of protein misfolding, amyloid-related toxicity, and inflammation.

Novacta Biosystems Ltd, founded in 2003, is a clinical-stage biopharmaceutical company focused on developing innovative treatments for bacterial infections, particularly those caused by drug-resistant bacteria. Utilizing expertise from GSK's Biotransformation and Natural Products scientific team, the company has established a dual business model that encompasses both the development of a therapeutic pipeline and the provision of biocatalysis and microbial pathway engineering services. Novacta specializes in the discovery, development, and commercialization of a novel class of small peptide molecules known as lantibiotics, which are designed to combat infections such as Clostridium difficile. Through its efforts, Novacta aims to address critical needs in the field of infectious diseases by providing effective anti-infective solutions.

Fovea Pharmaceuticals is a French biopharmaceutical company established in 2005, specializing in the discovery and development of drugs for ocular diseases. Based in Paris, Fovea focuses on creating innovative treatments for various eye conditions, including allergic conjunctivitis, hereditary angioedema, diabetic macular edema, and retinitis pigmentosa. The company's key products include FOV1101 Prednisporin, FOV2302, FOV2304, and FOV2501, which address a range of ocular disorders and associated complications. As of October 2009, Fovea operates as a subsidiary of Sanofi, enhancing its capabilities to deliver effective therapies for vision-related health issues.

Sentinel Oncology Limited is a drug discovery company based in Cambridge, United Kingdom, established in 2005. The company is focused on developing and commercializing therapeutics aimed at treating cancer, particularly for patients with unmet medical needs. Sentinel Oncology utilizes small molecule approaches to target the microenvironment of solid tumors. Its research and development pipeline includes programs such as Checkpoint Kinase 1, which activates in response to DNA damage and replication stress, and a novel drug targeting S6K1 to address metastatic breast cancer. Additionally, the company is advancing a strategy called "Targeted Synergy," designed to enhance the therapeutic index by delivering drug effects directly to the tumor. Sentinel Oncology aims to create high-quality drug candidates for collaboration with the biotechnology and pharmaceutical industries.

Lectus Therapeutics Limited is a UK-based pharmaceutical company dedicated to developing first-in-class therapeutics targeting ion channels. Utilising proprietary proteomics technology, Lectus aims to create innovative treatments focused on pain management and urinary bladder disorders.

Xtera Communications, Inc. was a provider of optical transport solutions, specializing in Raman amplification-enabled systems for terrestrial and submarine networks. Founded in 1998 and headquartered in Allen, Texas, the company catered to telecommunications service providers, content service providers, enterprises, and government entities globally. Xtera offered a range of products and services, including un-repeatered and repeatered optical systems, designed to enhance network reach and capacity. Its solutions were tailored to meet individual customer needs, encompassing full turnkey systems, open architecture designs, and specific product supply. Despite its previous success in expanding its customer base and product portfolio, Xtera faced financial difficulties that led to its Chapter 11 bankruptcy filing in November 2016, which was later converted to Chapter 7 liquidation in February 2017.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Kuur Therapeutics Limited is a biopharmaceutical company focused on developing, manufacturing, and commercializing CAR-NKT cell immunotherapies for cancer treatment. The company is advancing a pipeline of immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics specializes in engineered off-the-shelf CAR-NKT cell therapies that leverage the natural biology of a specific subset of cytotoxic T cells known as natural killer T cells. This innovative approach aims to provide effective treatment options for a wide range of solid and hematological tumors. The company conducts clinical trials to demonstrate the efficacy of its CAR-NKT cell products, thereby striving to transform cancer care. Founded in 2005 and based in London, Kuur Therapeutics was previously known as Cell Medica Limited before its rebranding in February 2020.